2,6-Dimethyl-4-oxa-1-heptanol | 64205-82-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,6-Dimethyl-4-oxa-1-heptanol
• 英文别名: 3-isobutoxy-2-methyl-propan-1-ol；2-Methyl-3-(2-methylpropoxy)propan-1-ol
• CAS: 64205-82-9
• 化学式: C₈H₁₈O₂
• 分子量: 146.23
• InChiKey: PANHWWFPMIFRHZ-UHFFFAOYSA-N

物化性质

• 沸点：
  206.0±8.0 °C(Predicted)
• 密度：
  0.885±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,6-Dimethyl-4-oxa-1-heptanol 生成 2-Butenamide,N,N-diethyl-3-methyl-4-[2-methyl-3-(2-methylpropoxy)propoxy]-
  参考文献：
  名称：

  Synthesis of some dioxa analogues of acyclic juvenoids

  摘要：

  DOI：

  10.1135/cccc19771894
• 作为产物：
  描述：

  2-Hydroxy-3-isobutoxy-2-methyl-propionic acid ethyl ester 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 2,6-Dimethyl-4-oxa-1-heptanol
  参考文献：
  名称：

  Synthesis of some dioxa analogues of acyclic juvenoids

  摘要：

  DOI：

  10.1135/cccc19771894

文献信息

• Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US20150111875A1

  公开（公告）日：2015-04-23

  The present invention relates to aminotetraline and aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.

  本发明涉及公式(I)的氨基四氢萘和氨基茚衍生物或其生理耐受的盐。该发明涉及包含此类氨基四氢萘和氨基茚衍生物的药物组合物，以及利用这些氨基四氢萘和氨基茚衍生物进行治疗目的的用途。氨基四氢萘和氨基茚衍生物是GlyT1抑制剂。
• Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US20150111867A1

  公开（公告）日：2015-04-23

  The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereof The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquin oline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.

  本发明涉及氨基色酮、氨基硫代色酮和氨基-1,2,3,4-四氢喹啉衍生物的化学式（I）或其生理耐受盐。该发明涉及包括这种氨基色酮、氨基硫代色酮和氨基-1,2,3,4-四氢喹啉衍生物的药物组合物，以及利用这种氨基色酮、氨基硫代色酮和氨基-1,2,3,4-四氢喹啉衍生物进行治疗目的的用途。这些氨基色酮、氨基硫代色酮和氨基-1,2,3,4-四氢喹啉衍生物是GlyT1抑制剂。
• Deuterium-enriched alkyl sulfonamides
  申请人：Dhanoa Daljit Singh

  公开号：US20110034479A1

  公开（公告）日：2011-02-10

  The present invention is concerned with deuterium-enriched isobutyl and cyclohexylmethyl sulfonamides of formula I and II, and pharmaceutically acceptable salts and methods of use thereof for the treatment of general anxiety disorders, major depressive disorders, attention deficit disorders, attention deficit hyperactivity disorder, Alzheimer's disease, frontotemporal dementia, cognitive impairment associated with age-related dementia, schizophrenia, migraine, sleep disorders, neurodegenerative diseases and obesity.

  本发明涉及公式I和II的氘富集异丁基和环己基甲基磺酰胺，以及其药学上可接受的盐和使用方法，用于治疗广泛性焦虑障碍、重度抑郁障碍、注意缺陷障碍、注意缺陷多动障碍、阿尔茨海默病、额颞型痴呆、与老年痴呆相关的认知障碍、精神分裂症、偏头痛、睡眠障碍、神经退行性疾病和肥胖症。
• PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY
  申请人：POHLKI Frauke

  公开号：US20120077796A1

  公开（公告）日：2012-03-29

  The present invention relates to phenalkylamine derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such phenalkylamine derivatives, and the use of such phenalkylamine derivatives for therapeutic purposes. The phenalkylamine derivatives are GlyT1 inhibitors.

  本发明涉及式(I)的苯基烷胺衍生物或其生理上可耐受的盐。本发明涉及包含这种苯基烷胺衍生物的制药组合物，以及使用这种苯基烷胺衍生物进行治疗的用途。这些苯基烷胺衍生物是GlyT1抑制剂。
• TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY
  申请人：Lange Udo

  公开号：US20120295881A1

  公开（公告）日：2012-11-22

  The present invention relates to tetraline and indane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such tetraline and indane derivatives, and the use of such tetraline and indane derivatives for therapeutic purposes. The tetraline and indane derivatives are GlyT1 inhibitors.

  本发明涉及式(I)的四氢萘和茚烷衍生物或其生理上可耐受的盐。本发明涉及包含这种四氢萘和茚烷衍生物的制药组合物，以及使用这种四氢萘和茚烷衍生物进行治疗目的的方法。这种四氢萘和茚烷衍生物是GlyT1抑制剂。